Literature DB >> 10852542

Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients.

W X Yan1, J Taylor, S Andrias-Kauba, J D Pollard.   

Abstract

Chronic inflammatory demyelinating polyneuropathy (CIDP) is regarded as an autoimmune disorder, but no clearly defined autoimmune mechanism has been described. Although most patients respond to plasma exchange, no convincing role for autoantibodies has yet been demonstrated. In this study, we have successfully passively transferred disease using sera and purified IgG from 4 of 12 patients responsive to plasma exchange by bypassing the blood-nerve barrier by intraneural injection or opening it by activated T cells. The sera from CIDP patients or purified IgG produced marked conduction block and demyelination, but normal sera or IgG or that from patients with multiple sclerosis or other neuropathies did not. These observations strongly support an important role for anti-myelin/Schwann cell autoantibodies in the pathogenesis of CIDP at least in some patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10852542

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  25 in total

Review 1.  Chronic inflammatory demyelinative polyneuropathy.

Authors:  Gérard Said
Journal:  J Neurol       Date:  2002-03       Impact factor: 4.849

Review 2.  Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy.

Authors:  Björn Tackenberg; Falk Nimmerjahn; Jan D Lünemann
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

3.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

4.  CD19 as a therapeutic target in a spontaneous autoimmune polyneuropathy.

Authors:  P M Abraham; S H Quan; D Dukala; B Soliven
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

Review 5.  Advances in the diagnosis, pathogenesis and treatment of CIDP.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

Review 6.  Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications.

Authors:  Luis Querol; Jérôme Devaux; Ricard Rojas-Garcia; Isabel Illa
Journal:  Nat Rev Neurol       Date:  2017-07-14       Impact factor: 42.937

7.  Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.

Authors:  Isaak Quast; Christian W Keller; Michael A Maurer; John P Giddens; Björn Tackenberg; Lai-Xi Wang; Christian Münz; Falk Nimmerjahn; Marinos C Dalakas; Jan D Lünemann
Journal:  J Clin Invest       Date:  2015-10-05       Impact factor: 14.808

8.  Severe refractory CIDP: a case series of 10 patients treated with bortezomib.

Authors:  Kalliopi Pitarokoili; Min-Suk Yoon; Ilka Kröger; Anke Reinacher-Schick; Ralf Gold; Christiane Schneider-Gold
Journal:  J Neurol       Date:  2017-08-23       Impact factor: 4.849

Review 9.  Immune-mediated neuropathies.

Authors:  Bernd C Kieseier; Emily K Mathey; Claudia Sommer; Hans-Peter Hartung
Journal:  Nat Rev Dis Primers       Date:  2018-10-11       Impact factor: 52.329

10.  Anti-Ganglioside Antibodies Induce Nodal and Axonal Injury via Fcγ Receptor-Mediated Inflammation.

Authors:  Lan He; Gang Zhang; Weiqiang Liu; Tong Gao; Kazim A Sheikh
Journal:  J Neurosci       Date:  2015-04-29       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.